SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
NOTIFICATION OF LATE FILING
Commission File Number: 333-193220
|(Check One):||[ ] Form 10-K||[ ] Form 20-F||[ ] Form 11-K||[X] Form 10-Q|
|[ ] Form 10-D||[ ] Form N-SAR||[ ] Form N-CSR|
For Period Ended: December 31, 2017
|[ ] Transition Report on Form 10-K||[ ] Transition Report on Form 20-F|
|[ ] Transition Report on Form 11-K||[ ] Transition Report on Form 10-K|
|[ ] Transition Report on Form N-SAR|
Form the transition period ended:
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART I – REGISTRANT INFORMATION
NuLife Sciences, Inc.
Full Name of Registrant
Former Name if Applicable
2618 San Miguel, Suite 203
Address of Principal Executive Office (Street and Number
Newport Beach, CA 922660
City, State and Zip Code
PART II – RULES 12b-25 (b) and (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25 (b), the following should be completed. (Check box if appropriate)
[ X ] (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
[ X ] (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
[ ] (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
PART III – NARRATIVE
State below in reasonable detail why forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, or the transition report or portion thereof, could not be filed within the prescribed time period.
Due to unforeseeable circumstances financial information to be contained in registrants 10-Q for the quarter ended December 31, 2017 cannot be analyzed and completed on a timely basis.
|(1)||Name and telephone number of person to contact in regard to this notification|
Fred Luke (949) 973-0684
|(2)||Have all other periodic reports required under Section 13 or 15(d) or the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed If the answer is no, identify report(s).|
[ X ] Yes [ ] No
|(3)||Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?|
[ ] Yes [ X ] No
If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
NuLife Sciences, Inc.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.
|Date: February 14, 2018||By:||/s/ Fred Luke|